- Home
- SLP vs CERS Comparison
SLP vs CERS Comparison
Compare SLP & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLP
- CERS
- Stock Information
- Founded
- SLP 1996
- CERS 1991
- Country
- SLP United States
- CERS United States
- Employees
- SLP N/A
- CERS N/A
- Industry
- SLP EDP Services
- CERS EDP Services
- Sector
- SLP Technology
- CERS Technology
- Exchange
- SLP Nasdaq
- CERS Nasdaq
- Market Cap
- SLP 282.4M
- CERS 255.0M
- IPO Year
- SLP 1997
- CERS 1997
- Fundamental
- Price
- SLP $15.43
- CERS $1.23
- Analyst Decision
- SLP Buy
- CERS Strong Buy
- Analyst Count
- SLP 7
- CERS 2
- Target Price
- SLP $29.50
- CERS $3.50
- AVG Volume (30 Days)
- SLP 445.5K
- CERS 1.1M
- Earning Date
- SLP 10-22-2025
- CERS 10-29-2025
- Dividend Yield
- SLP N/A
- CERS N/A
- EPS Growth
- SLP N/A
- CERS N/A
- EPS
- SLP N/A
- CERS N/A
- Revenue
- SLP $80,383,000.00
- CERS $192,510,000.00
- Revenue This Year
- SLP $12.75
- CERS $22.02
- Revenue Next Year
- SLP $3.06
- CERS $9.32
- P/E Ratio
- SLP N/A
- CERS N/A
- Revenue Growth
- SLP 20.01
- CERS 13.25
- 52 Week Low
- SLP $12.39
- CERS $1.12
- 52 Week High
- SLP $37.67
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- SLP 60.71
- CERS 45.54
- Support Level
- SLP $13.78
- CERS $1.17
- Resistance Level
- SLP $14.46
- CERS $1.27
- Average True Range (ATR)
- SLP 0.62
- CERS 0.06
- MACD
- SLP 0.19
- CERS -0.00
- Stochastic Oscillator
- SLP 71.91
- CERS 33.33
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.